Acute and chronic experimental Trypanosoma cruzi infection in the rat. Response to systemic treatment with recombinant rat interferon-gamma. 1995

S Revelli, and H Davila, and M E Ferro, and M Romero-Piffiguer, and O Musso, and J Valenti, and J Bernabo, and E Falcoff, and J Wietzerbin, and O Bottasso
Instituto de Inmunología, Facultad de Ciencias Médicas Universidad Nacional de Rosario, Argentina.

We examined the effects of recombinant rat interferon-gamma (IFN-gamma) injections on the parasitologic, serologic, immunologic and histopathologic features of acute and chronic experimental Trypanosoma cruzi (T. cruzi) infections in "l" rats. Upon infection at weaning, two rat groups were allocated to receive a 20-day cycle of IFN-gamma injections, 20,000 IU/rat each, which started at 1, and 7 days post-infection (pi). Treatment with IFN-gamma, initiated at either 1 or 7 days pi, resulted in comparatively lower peak parasitemias (P < 0.02) but in similar levels of anti-T. cruzi circulating antibodies and serum IFN-gamma activities. The latter appeared significantly increased during acute infection whereas biologically active tumor necrosis factor was virtually undetectable in serum from infected rats regardless of whether they had been given IFN-gamma or not. The prevalence of chronic focal myocarditis in IFN-gamma-treated infected rats showed no differences with respect to the one recorded in control-infected counterparts. The inverse CD4/CD8 ratio of spleen and lymph node T cells that usually accompanies chronic infection was reversed by IFN-gamma. Mononuclear cells carrying class II I-A and I-E molecules, that were found to have increased at both compartments, appeared also modified upon IFN-gamma treatment with an overincrease of I-A-positive cells, and a normalization of I-E-bearing cells.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D008297 Male Males
D009205 Myocarditis Inflammatory processes of the muscular walls of the heart (MYOCARDIUM) which result in injury to the cardiac muscle cells (MYOCYTES, CARDIAC). Manifestations range from subclinical to sudden death (DEATH, SUDDEN). Myocarditis in association with cardiac dysfunction is classified as inflammatory CARDIOMYOPATHY usually caused by INFECTION, autoimmune diseases, or responses to toxic substances. Myocarditis is also a common cause of DILATED CARDIOMYOPATHY and other cardiomyopathies. Carditis,Myocarditides
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000913 Antibodies, Protozoan Immunoglobulins produced in a response to PROTOZOAN ANTIGENS. Protozoan Antibodies

Related Publications

S Revelli, and H Davila, and M E Ferro, and M Romero-Piffiguer, and O Musso, and J Valenti, and J Bernabo, and E Falcoff, and J Wietzerbin, and O Bottasso
May 1991, Infection and immunity,
S Revelli, and H Davila, and M E Ferro, and M Romero-Piffiguer, and O Musso, and J Valenti, and J Bernabo, and E Falcoff, and J Wietzerbin, and O Bottasso
January 1992, The Journal of experimental medicine,
S Revelli, and H Davila, and M E Ferro, and M Romero-Piffiguer, and O Musso, and J Valenti, and J Bernabo, and E Falcoff, and J Wietzerbin, and O Bottasso
September 1998, Cytokines, cellular & molecular therapy,
S Revelli, and H Davila, and M E Ferro, and M Romero-Piffiguer, and O Musso, and J Valenti, and J Bernabo, and E Falcoff, and J Wietzerbin, and O Bottasso
January 1997, Medicina,
S Revelli, and H Davila, and M E Ferro, and M Romero-Piffiguer, and O Musso, and J Valenti, and J Bernabo, and E Falcoff, and J Wietzerbin, and O Bottasso
January 1999, Medicina,
S Revelli, and H Davila, and M E Ferro, and M Romero-Piffiguer, and O Musso, and J Valenti, and J Bernabo, and E Falcoff, and J Wietzerbin, and O Bottasso
January 2015, PloS one,
S Revelli, and H Davila, and M E Ferro, and M Romero-Piffiguer, and O Musso, and J Valenti, and J Bernabo, and E Falcoff, and J Wietzerbin, and O Bottasso
April 1991, The Journal of infectious diseases,
S Revelli, and H Davila, and M E Ferro, and M Romero-Piffiguer, and O Musso, and J Valenti, and J Bernabo, and E Falcoff, and J Wietzerbin, and O Bottasso
January 1987, Annales de l'Institut Pasteur. Immunology,
S Revelli, and H Davila, and M E Ferro, and M Romero-Piffiguer, and O Musso, and J Valenti, and J Bernabo, and E Falcoff, and J Wietzerbin, and O Bottasso
November 2001, Phytotherapy research : PTR,
S Revelli, and H Davila, and M E Ferro, and M Romero-Piffiguer, and O Musso, and J Valenti, and J Bernabo, and E Falcoff, and J Wietzerbin, and O Bottasso
January 1969, Annals of the New York Academy of Sciences,
Copied contents to your clipboard!